Tolerion's second wind

Tolerion aims to turn down Type I diabetes autoimmune cells

Armed with positive Phase IIa data in Type I diabetes, Tolerion Inc. is now seeking funding for a second go at developing a selective immunomodulatory approach that previously failed in multiple sclerosis.

In 2011, Tolerion plucked TOL-3021 from the ashes of defunct autoimmune disease company Bayhill Therapeutics Inc., which wound down after BHT-3009 failed in a Phase IIb trial to treat MS.

While the two products have a similar design, Tolerion says an important difference is that

Read the full 752 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE